Zillow Group, Inc. (NASDAQ:ZG)
Zillow Group, Inc. (NASDAQ:ZG) represented a move of -0.44 percent or $-0.22 per share and closed its previous day trading session at $36.23. 1.04 Million Shares were traded in the last trading session with an Average Volume of 935.1 Million Shares. The stock currently has a Market Capitalization of 7.42 Billion.
Zillow Group, Inc. provides real estate and home-related brands on the Web and mobile. The company focuses on home lifecycle which include renting, buying, selling, financing and home improvement. Its portfolio of consumer brands consists of Zillow(R), Trulia(R), StreetEasy(R) and HotPads(R). The company’s business brands includes ActiveRain(R), Diverse Solutions(R), Market Leader(R), Mortech(R), Postlets(R) and Retsly(TM). Zillow Group Inc., formerly known as Zillow Inc., is headquartered in Seattle.
The stock traded between $26.20 and $65.42 over 1-Year time period showing its price to sales ratio of 5.93. Zillow Group, Inc. (NASDAQ:ZG) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-3.47 and 200-Day Simple Moving Average of $-27.4. Its Price to Free Cash Flow is 42.87 and Price to Book of 2.21.
Analyst’s recommended the stock as 2.7 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Zillow Group, Inc. (NASDAQ:ZG) reported its Actual EPS of $0.18/share. The analysts offering Earnings Estimates for the company were believing that Zillow Group, Inc. could bring EPS of $0.17/share. The difference between Actual EPS and Estimated EPS was 0.01 Percent. Thus showing an Earnings Surprise of 5.9 Percent.
Sierra Oncology, Inc. (NASDAQ:SRRA)
In the last trading session, Sierra Oncology, Inc. (NASDAQ:SRRA) added its value by -4.68% closing at the price of $1.63. The stock currently has market capitalization of 127.21 Million, with average volume of 569.9 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Sierra Oncology, Inc. (NASDAQ:SRRA) is showing beta of 1.72. This particular value of beta suggests that Sierra Oncology, Inc. (NASDAQ:SRRA) has historically moved 172% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Sierra Oncology, Inc. (NASDAQ:SRRA) is at $-0.63.
The stock currently has RSI of 45.66. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central regulator of the DNA Damage Response network. SRA141 is an orally available small molecule inhibitor of cell division cycle 7kinase. Sierra Oncology, Inc., formerly known as ProNAi Therapeutics, Inc., is headquatered in Vancouver, Canada.
Sierra Oncology, Inc. (NASDAQ:SRRA) topped its 52-week high price of $4.09 on 12/27/17 and 52-Week Low Price of $1.48 on 10/11/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 8.20% and monthly volatility of 7.19% respectively.